Nephrology Drugs Market 2024 Analysis By Size, Share, Growth, Trends Up To 2033 | AstraZeneca plc, AbbVie Inc., Akebia Therapeutics Inc., Amgen Inc., F. Hoffmann-La Roche AG

"The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.

Nephrology Drugs Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.

The Market Size Is Expected To Reach $21.53 billion In 2028 At A CAGR Of 6.0% :

The nephrology drugs market size has grown strongly in recent years. It will grow from $16.18 billion in 2023 to $17.08 billion in 2024 at a compound annual growth rate (CAGR) of 5.6%. The growth in the historic period can be attributed to rising prevalence of chronic kidney diseases (ckd), advancements in drug development, increasing awareness and diagnosis, government initiatives and healthcare policies, increasing incidence of diabetes.

The nephrology drugs market size is expected to see strong growth in the next few years. It will grow to $21.53 billion in 2028 at a compound annual growth rate (CAGR) of 6.0%. The growth in the forecast period can be attributed to emerging therapies and drug innovations, precision medicine and personalized treatment approaches, increasing healthcare expenditure, telehealth and remote patient monitoring, global health initiatives. Major trends in the forecast period include collaborations and partnerships, technological advancements in dialysis, advancements in treatment modalities, growing emphasis on early diagnosis and intervention, technological integration in nephrology management.

Request A Sample Of This Report - https://www.thebusinessresearchcompany.com/sample.aspx?id=10076&type=smp

Nephrology Drugs Market Major Segments
The nephrology drugs market covered in this report is segmented -

1) By Drugs: Antihypertensive Agents, Erythropoiesis-Stimulating Agents, Diuretics, ACE Inhibitors, Antidiabetic Agents, Other Drugs
2) By Route Of Administration: Oral, Parenteral, Other Route Of Administration
3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Key Driver - Addressing The Silent Epidemic The Growing Prevalence Of Chronic Kidney Disease Fuels Expansion In The Nephrology Drugs Market

The rising prevalence of chronic kidney disease is expected to propel the growth of the nephrology drugs market going forward. Chronic kidney disease (CKD) refers to damaged kidneys that are unable to filter blood as effectively as they should. because kidney damage develops gradually over a lengthy period of time. Wastes could accumulate in the body as a result of this injury. Nephrology drugs are primarily used in the treatment of chronic kidney disease to enhance kidney function and slow the disease, preventing it from doing more harm to the body, so these factors boost the nephrology drug market. For instance, in July 2022, according to reports shared by the Centers for Disease Control and Prevention (CDC), a US-based health protection agency, it was estimated that in the US, more than 37 million people were diagnosed with chronic kidney disease, which is more common in people aged 65 years or older (38 percent). Furthermore, according to the Kidney Foundation of Canada, a Canada-based non-profit organization, 4 million Canadians are suffering from kidney diseases. 35 percent of diabetic patients are the leading cause of kidney failure. These numbers are expected to rise in the future. Therefore, the rising prevalence of chronic kidney disease is driving the growth of the nephrology drug market.

Customise This Report As Per Your Requirements - https://www.thebusinessresearchcompany.com/Customise?id=10076&type=smp

Prominent Trend - Zydus Lifesciences Introduces Oxemiatm A Novel Hif-Ph Inhibitor Elevating Treatment Options In The Nephrology Drug Market

Product innovation is a key trend gaining popularity in the nephrology drug market. Major companies operating in the nephrology drug market are innovating new products and drugs to sustain their position in the market. For instance, in March 2022, Zydus Lifesciences Limited., an Indian-based pharmaceutical company, launched OxemiaTM (desidustat) for chronic kidney disease (CKD). It is an oral, small-molecule hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitor with a convenient therapeutic option for the treatment of anemia. And approved by the Drug Controller General of India. in Phase III clinical trials It demonstrated good safety profiles, hepcidin downregulation, better iron mobilization, and a reduction in LDL-C in chronic kidney disease patients. Also, by providing treatment at a reasonable price and enhancing patients quality of life, this will lessen the burden of disease.

Nephrology Drugs Market Players
Major companies operating in the nephrology drugs market report are AstraZeneca plc, AbbVie Inc., Akebia Therapeutics Inc., Amgen Inc., F. Hoffmann-La Roche AG, FibroGen Inc., Johnson And Johnson, Pfizer Inc., GlaxoSmithKline plc, Teva Pharmaceutical Industries Limited, Boehringer Ingelheim International GmbH, Reata Pharmaceuticals Inc., Ardelyx Inc., Novo Nordisk A/S, Novartis AG, Baxter International Inc., Bristol Myers Squibb Company, Kissei Pharmaceutical Co. Ltd., Kyowa Kirin Co. Ltd., Mallinckrodt Pharmaceuticals, OPKO Health Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Vifor Pharma Group, Bayer AG, Amicus Therapeutics, Chugai Pharmaceutical Co. Ltd., Otsuka Pharmaceutical Co. Ltd., Mylan N.V., Endo Pharmaceuticals plc

View The Full Report Here - https://www.thebusinessresearchcompany.com/report/nephrology-drugs-global-market-report

Largest And Fastest Growing Region In The Market
North America was the largest region in the nephrology drug market in 2023. Europe will be the second-largest growing region in the nephrology drug market in 2023. The regions covered in the nephrology drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The Table Of Content For The Market Report Include:
1. Executive Summary
2. Nephrology Drugs Market Report Structure
3. Nephrology Drugs Market Trends And Strategies
4. Nephrology Drugs Market - Macro Economic Scenario
5. Nephrology Drugs Market Size And Growth
…..
27. Nephrology Drugs Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ "

Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.